gastroduodenal ulcer
Conditions
Interventions
The subjects were allocated to either the famotidine group (20 mg, once a day)hey were treated with each study medication for 12 weeks while taking LDA continuously
the teprenone group (50 mg, three t
Sponsors
Osaka Medical College
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: criteria were that patients required continuous medication with LDA (80–300 mg/day) for 12 weeks or longer after participation in the study, regardless of past LDA treatment, that they were aged 20 years or older and that no peptic ulcer was detected on endoscopy at the start of treatment. Patients were included regardless of sex and whether or not they were outpatients. Exclusion criteria were as follows:
Exclusion criteria
Exclusion criteria: 1) Patients with peptic ulcer; 2) Patients who had undergone gastrectomy or vagotomy; 3) Patients treated with an H2RA or PPI within the 28 days (four weeks) before the start of study medication administration; 4) Patients treated with a non-steroidal anti-inflammatory drug (NSAID) within 28 days (four weeks) before the start of study medication administration; 5) Patients whose corticosteroid regimen (excluding topical medication) was changed (including the dosage and administration) within 14 days (two weeks) before the start of study medication administration; 6) Patients with a serious liver disorder, a serious renal disorder, a serious cardiac disease, and/or a serious blood dyscrasia; 7) Patients who were allergic to or had experienced an adverse reaction to famotidine or teprenone, which scheduled to be administered; 8) Pregnant or lactating women, or women who might become or intended to become pregnant during the study period; 9) Patients determined by an investigator or a sub-investigator to be ineligible.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endoscopy view (existence of ulcer development of symptoms) | — |
Secondary
| Measure | Time frame |
|---|---|
| A LANZA strange method score, subjective symptoms, a blood test (anemic existence), safety | — |
Countries
Japan
Contacts
Public ContactToshihisa Takeuchi
Osaka Medical College 2nd Department of Internal Medicine
Outcome results
None listed